Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
JAK Inhibitors and Granulomatous Diseases Update
Description
The presentation discusses recent advancements in the use of JAK inhibitors for treating granulomatous diseases, particularly sarcoidosis, and granuloma annulare (GA). The speaker shares personal experiences with patients who had recalcitrant sarcoidosis, detailing how those who failed conventional treatments saw significant improvements when treated off-label with tofacitinib, a JAK inhibitor. The activation of the JAK-STAT signaling pathway in sarcoidosis is emphasized, revealing high levels of pathway activation in granuloma tissues. Following promising case reports, a clinical trial with 10 sarcoidosis patients was conducted, yielding notable results where most participants experienced resolution of skin lesions and decreased disease activity. Additionally, a similar open-label study for GA showed positive responses to tofacitinib, indicating a broader potential for JAK inhibitors in treating these conditions. The speaker calls for further controlled studies to validate these findings and express optimism about the future of alternative JAK inhibitors in managing these diseases.
View moreConclusions
- JAK inhibitors, specifically tofacitinib, show promise in treating recalcitrant cutaneous sarcoidosis, leading to significant clinical improvement.
- In a clinical trial, six out of ten patients with skin sarcoidosis achieved complete clinical responses after six months of tofacitinib treatment.
- The mechanism of action for tofacitinib involves the inhibition of the JAK-STAT signaling pathway, particularly affecting interferon gamma signaling, which is central to sarcoidosis pathogenesis.
- Patients on tofacitinib were able to reduce or discontinue the use of other immunosuppressive therapies, suggesting a favorable risk/benefit profile for this treatment.
- There is evidence of significant activation of the JAK-STAT pathway in sarcoidosis patients, justifying the use of JAK inhibitors for treatment.
- Further investigations into other JAK inhibitors and their efficacy in granulomatous diseases like granuloma annulare are currently ongoing, highlighting the need for larger controlled studies.
- lannuzzi et al. N Engl J Med 2007
- Drent et al. N Engl J Med 2021
- Damsky et al. New Engl J Med 2018
- Damsky et al. J Am Acad Dermatol 2020
- Damsky et al. Nature Communications 2022
- Damsky et al. Nature Communications in press
- Cohen et al. Br J Dermato 2023; 188: 134-154
- Wang et al. J All Clin Immunol 2020
- Sondermann et al. (publication details not provided)